Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Dec;27(6):625-44.
doi: 10.1023/a:1020930626404.

A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron

Affiliations

A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron

E H Cox et al. J Pharmacokinet Biopharm. 1999 Dec.

Abstract

This paper presents and illustrates methodology for specifying, estimating, and evaluating a predictive model for repeated measures time-to-event responses. The illustrative example specifies a model of the antiemetic effect vs. concentration relationship for the 5-HT3 antagonist ondansetron in the human ipecac model for emesis. A key part of this model is a time-dependent log hazard function for emesis that is increased by ipecac administration and decreased by ondansetron concentration. The model is fit using an approximate maximum likelihood method. The data consist of the time free of emeses and, for those individuals with emetic episodes, the time(s) of the episode(s). Model evaluation is accomplished using residual plots adapted to time-to-event data and a "posterior predictive check" wherein observed data statistics are compared to those obtained from data simulated from the fitted model. The ondansetron concentration required to obtain a 50% reduction in the hazard of emesis is estimated to be 1.4 +/- 0.2 ng/ml, and the rate constant for elimination of ipecac-induced hazard is 1.5 +/- 0.2 hr-1.

PubMed Disclaimer

References

    1. J Pharmacokinet Biopharm. 1992 Oct;20(5):511-28 - PubMed
    1. Clin Pharmacol Ther. 1994 Sep;56(3):309-22 - PubMed
    1. J Pharm Biomed Anal. 1994 Mar;12(3):361-71 - PubMed
    1. J Clin Pharmacol. 1996 Sep;36(9):767-70 - PubMed
    1. J Pharm Sci. 1991 Sep;80(9):868-71 - PubMed

Publication types

LinkOut - more resources